Chemopreventive effect of Pingxiao capsule on breast cancer in rats and its mechanism

doi:10.3877/cma.j.issn.1674-0807.2013.05.004

Abstract

Abstract:

Objective

To investigate the chemopreventive effect of Pingxiao capsule on breast cancer in rats and its mechanism.

Methods

A total of 60 21-day-old female SD rats were randomly divided into three groups,20 rats in each group.All rats were intraperitoneally injected with methylnitrosourea.After that, water was provided to rats in group A (negative control group), water mixed with Pingxiao capsules in group B(Pingxiao capsule group), water solved with tamoxifen in Group C (tamoxifen group).The number and volume of the tumors developed in rats of each group were recorded.All rats were sacrificed at age of 98 days,and then the breast cancer tissue was sampled for HE staining and pathological detection.VEGF expression and microvessel density (MVD) in rat breast invasive ductal carcinoma (IDC) were determined by SP immunohistochemistry.χ² test and one-way analysis of variance were conducted for data analysis.

Results

The occurrence of IDC was 100%(20/20)in group A, 60.0%(12/20) in group B and 50.0%(10/20) in group C, respectively, which presented a statisticaly significant difference among the three groups(χ² =13.33,P=0.001).The occurrence of IDC in group B was lower than that in group A(P＜0.017), but there was no statistical difference between group B and group C (χ²=0.40,P＞0.017).The volume of tumors was (1042±102) mm³ in group A,(398±42) mm³ in group B and (520±33) mm³ in group C,respectively,which showed a statistical difference among the three groups (F=4.99,P=0.010).The average volume of tumors in group B was less than that in group A(P=0.009), but there was no statistical difference between group B and group C(P=0.120).The positive rate of VEGF in IDC tissue was 83.3% in group A,42.6% in group B and 75.3%in group C, respectively (χ²=37.71,P=0.000 ).The positive rate of VEGF in group B was significantly lower than that in group A (χ²=35.84,P＜0.017)and group C (χ²=16.07,P＜0.017).MVD of IDC was 68.2±8.6 in group A,29.6±1.2 in group B and 59.1±7.1 in group C, respectively (F=4.31,P=0.015 ).MVD in group B was lower than that in group A and group C (all P=0.000).

Conclusions

Pingxiao capsules can inhibit the development of breast cancer in rats, which may be due to its anti-angiogenesis effect.So Pingxiao capsules have chemopreventive effects on breast cancer in rats.

Key words: Breast neoplasms, Chemoprevention, Pingxiao capsule

Xiao-rong HAN, Jian-min YANG, Yi-zhong LUO, Ni HAN, Jian-jun LI, Qi WANG. Chemopreventive effect of Pingxiao capsule on breast cancer in rats and its mechanism[J]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(05): 329-333.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2013.05.004

https://zhrxbzz.cma-cmc.com.cn/EN/Y2013/V07/I05/329

Figures/Tables 7

References 13

[1]	Reimers L, Crew KD.Tamoxifen vs raloxifene vs exemestane for chemoprevention [J].Curr Breast Cancer Rep,2012,4(3):207-215.
[2]	Den Hollander P, Savage MI, Brown PH.Targeted therapy for breast cancer prevention[J].Front Oncol,2013,3:250.
[3]	刘健,刘韬,谢佐福,等.平消胶囊抗肿瘤分子的生物学机制[J].福建医科大学学报,2006,40(4):368-372.
[4]	Kubatka P, Stollárová N, ^Skarda J,et al.Preventive effects of fluvastatin in rat mammary carcinogenesis[J].Eur J Cancer Prev,2013,22(4):352-357.
[5]	Russo J, Russo IH.Atlas and histologic classification of tumors of the rat mammary gland [J].J Mammary Gland Biol Neoplasia,2000,5(2):187-200.
[6]	韩晓蓉,郜红艺,吴坤河,等.三阴性乳腺癌中血管内皮生长因子C 的表达及其意义[J/CD].中华乳腺病杂志:电子版,2010,4(6):671-675.
[7]	Bˇadescu A, Georgescu CV, Vere CC, et al.Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer[J].Rom J Morphol Embryol,2012,53(4):997-1005.
[8]	Fisher B, Costantino JP, Wickerham DL, et al.Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study[J].J Natl Cancer Inst,2005,97(22):1652-1662.
[9]	Cuzick J, Forbes JF, Sestak I, et al.Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-1 trial[J].J Natl Cancer Inst,2007,99(4):272-282.
[10]	Goss PE, Ingle JN, Martino S, et al.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer[J].N Engl J Med,2003,349(19):1793-1802.
[11]	Roberts N,Kloos B,Cassella M,et al.Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2[J].Cancer Res,2006,66(5):2650-2657.
[12]	杨剑敏,王颀,李文萍.Suramin 对实验性大鼠乳腺癌化学预防作用的研究[J].中华肿瘤防治杂志,2011,18(7):494-497.
[13]	朱庆贵.平消胶囊抗肺癌的分子生物学机制[J].南方医科大学学报,2008,28(11):2069-2071.

组别	鼠数	肿瘤		肿瘤体积(mm³)	MVD计数(个)
组别	鼠数	发生数(只)	发生率(%)	肿瘤体积(mm³)	MVD计数(个)
A组(空白对照组)	20	20	100	1042±1028	68.2±8.6
B组(平消胶囊组)	20	12	60^ab	398±42^cd	29.6±1.2^e
C组(他莫昔芬组)	20	10	50	520±33	59.1±7.1
检验值		χ ²=13.33		F=4.99	F=4.31
P值		0.001		0.010	0.015

组别	鼠数	肿瘤		肿瘤体积(mm³)	MVD计数(个)
组别	鼠数	发生数(只)	发生率(%)	肿瘤体积(mm³)	MVD计数(个)
A组(空白对照组)	20	20	100	1042±1028	68.2±8.6
B组(平消胶囊组)	20	12	60^ab	398±42^cd	29.6±1.2^e
C组(他莫昔芬组)	20	10	50	520±33	59.1±7.1
检验值		χ ²=13.33		F=4.99	F=4.31
P值		0.001		0.010	0.015

组别	肿瘤数(个)	VEFG表达
组别	肿瘤数(个)	阳性数(个)	阳性率(%)
A组(空白对照组)	138	115	83.3
B组(平消胶囊组)	68	29	42.6^a
C组(他莫昔芬组)	77	58	75.3^b
χ ²值		37.71
P值		0.000

组别	肿瘤数(个)	VEFG表达
组别	肿瘤数(个)	阳性数(个)	阳性率(%)
A组(空白对照组)	138	115	83.3
B组(平消胶囊组)	68	29	42.6^a
C组(他莫昔芬组)	77	58	75.3^b
χ ²值		37.71
P值		0.000

[1]	Yang Li, Jinyu Cai, Xiaozhi Dang, Wanying Chang, Yan Ju, Yi Gao, Hongping Song. Application value of a deep learning-based model for generating strain elastography images using breast grayscale ultrasound images [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 563-570.
[2]	Collaboration Group，Breast Cancer Specialty Committee，Hebei Anti-Cancer Association Nursing. Expert consensus on nursing management of central venous access in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 321-329.
[3]	Chenlu Liu, Jie Liu, Fan Zhang, Caiying Yan, Qian Chen, Shuangqing Chen. Habitat analysis based on enhanced MRI radiomic features in predicting HER-2 expression in breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 339-345.
[4]	Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[5]	Lin Qiu, Jinhui Liu, Tuerhong Zumureti, Yuexin Ma, Xiaoling Leng. Diagnostic value of ultrasound radiomics in non-mass breast cancer in dense breasts [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 353-360.
[6]	Rui Ge, Fei Chen, Jie Li, Juanjuan Li, Han Chen. Application of multi-gene panel testing in adjuvant therapy for early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(05): 257-263.
[7]	Liu Yang, Zhenchuan Song, Xinle Wang. Clinical efficacy evaluation of modified radical mastectomy combined with latissimus dorsi muscle repositioning [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(05): 269-273.
[8]	Rui Wang, Jun Deng, Tingxin Shi, Zhizhao Zhang, Chengfang Wang, Yi Zhang, Xiaowei Qi. FAM91A1 is a potential prognostic factor in breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(05): 274-280.
[9]	Sihan Ji, Xinyu Tang, Bangjie Wang, Wenyang Di, Jiaming Wang, Xiaoming Zha, Hui Xie, Wenbin Zhou, Hong Pan, Shui Wang. Safety of abemaciclib in hormone receptor-positive/HER-2 negative breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(05): 281-286.
[10]	Mengmeng Han, Xueyuan Feng, Ning Ma. A case of radial nerve injury after modified radical surgery for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 117-118.
[11]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[12]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[13]	Lingyan Wang, Chunhui Gao, Xueyuan Feng, Xinmiao Cui, Huan Liu, Wenming Zhao, Jinku Zhang. Application of circulating tumor cells in neoadjuvant and postoperative adjuvant therapy for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 630-633.
[14]	Linjuan Zhao, Jie Lv, Wensheng Wang, Demao Ma, Tao Hou. Study on the effect of ultrasound guided resection of stellate and cylindrical lactation preserving areas with staining marks [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 634-637.
[15]	Chengxin Huang, Li Chen, Yichu Liu, Shuiliang Wang, Xiaofeng Lai. Expression characterization OPA1 expression in breast cancer tissues and its biological function in ER-positive breast cancer cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(05): 275-284.

Please choose a citation manager

Content to export